Indicated for: leukemia
Route of administration: injectable
Substance: daunorubicin (antineoplastic agent)
ATC: L01DB02 (Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Anthracyclines and related substances)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Daunorubicin is a chemotherapy drug used for the treatment of acute leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It belongs to the anthracycline class and works by inhibiting DNA synthesis in cancer cells, preventing their division.
The medication is administered intravenously and is often used in combination with other chemotherapy drugs to enhance treatment effectiveness. It is effective in inducing remission in patients with acute leukemia.
Side effects may include nausea, vomiting, hair loss, bone marrow suppression, and an increased risk of infections. In rare cases, it may cause cardiac toxicity. Close monitoring is essential during treatment.
Consult your doctor to discuss the benefits and risks of treatment with Daunorubicin. Follow all medical recommendations to minimize associated risks.